ADMA, an endogenous nonselective NOS inhibitor, is closely related to the development of endothelial dysfunction and atherosclerosis, and is suggested to be involved in an increased risk of cardiovascular diseases and stroke. This evidence concerns the gene NOS1 and endothelial dysfunction.